Bridge Neurotech's Latest Funding Round
Bridge Neurotech, a company based in Silicon Valley, California, has successfully raised $13.5 million in a recent funding round. The lead investor for this round is General Catalyst, with additional participation from reMind Capital, Sunflower Capital, and Scott Sandell. The company is focused on developing a non-invasive brain-computer interface (BCI) that utilizes ultrasound technology to image brain activity without the need for surgical intervention.
Company Mission and Technology
Bridge Neurotech aims to revolutionize the way brain activity is monitored and interpreted by utilizing functional ultrasound imaging. This approach allows for the observation of neural activity changes using ultrasound, offering a less invasive alternative to current implantable BCIs. The company's technology seeks to expand access to BCIs beyond the small number of individuals who have undergone neurosurgery for implantable devices.
The founder and CEO, Will Biederman, noted that, "Recent advancements in neuroscience, semiconductors, and artificial intelligence have made it increasingly feasible to develop a practical, non-invasive ultrasound-based BCI."
Use of Funds
The funds raised in this round will be used to further develop Bridge Neurotech's innovative technology. The company plans to focus on integrating advancements in semiconductor technology and artificial intelligence to enhance the functionality and accessibility of their brain-computer interface.
Future Developments
With the support from prominent investors, Bridge Neurotech is poised to continue its research and development efforts. The company is currently enrolling participants for its first research study in Redwood City, California, which will be crucial for testing and refining its non-invasive brain-computer interface.
Bridge Neurotech's innovative approach has the potential to significantly impact the field of neuroscience and broaden the application of BCIs in various sectors.